FDA approves Iperia ProMRI HF-T cardiac resynchronization defibrillator for heart failure- Biotronik
The FDA has announced approval of Iperia ProMRI HF-T, a cardiac resynchronization defibrillator, from Biotronik, that provides heart failure patients with access to diagnostic magnetic resonance imaging (MRI) scans. The Iperia HF-T was developed with Biotronik's ProMRI, Home Monitoring, and CLS technology, creating an advanced cardiac resynchronization therapy defibrillator (CRT-D) which ensures patients have access to 1.5T scans without an exclusion zone. Home Monitoring provides automatic daily transmission of data relating to arrhythmic events and heart failure statistics, which have been shown to reduce all-cause mortality by more than 50 percent.
Related news and insights
SpringWorks Therapeutics, Inc. announced that the FDA has approved Ogsiveo (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment
Protagonist Therapeutics, Inc. announced two additional Phase III studies, ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, evaluating JNJ 2113 (formerly PN 235) in head-to-head comparisons against deucravacitinib, an oral TYK2 inhibitor, in patients with moderate-to-severe psoriasis
Biotronik announced the presentation of two-year results from the investigator-initiated BIOPACT RCT by Principal Investigator Dr. Koen Deloose at the Paris Vascular Insights 2023 congress